We suggest that such changes in the bone microenvironment may be monitored, or even prevented, to specifically suppress late bone metastatic recurrence of ER+ tumors, because many patients are at risk for osteoporosis and vascular accident after menopause induced naturally, by estrogen block or even by chemotherapy-induced ovarian failure. Here, ESR1 is linked to ovarian dysfunction.